CANTON, Mass., Feb. 12 /PRNewswire-FirstCall/ -- Avitar, Inc. (Amex: - ) announced that it has hired Peter Cholakis for the position of Vice President of Marketing. Mr. Cholakis, who has more than 20 years of senior marketing experience, will lead Avitar's marketing function in penetrating the $1.5 billion drugs-of-abuse market with its point-of-care oral fluid drugs-of-abuse test, ORALscreen(TM).
Before joining Avitar, Peter Cholakis worked for VFA, a Boston-based enterprise software and services firm, as Vice President of Marketing. Prior to that he also held key marketing and sales positions in the high tech product and consultative services markets.
"We are very excited about having a marketing professional like Peter join our senior management team," said Peter P. Phildius, Chairman of Avitar. "The wider acceptance of oral fluid products to test for drugs of abuse has been accomplished. Having someone of Peter's caliber to help shape the ORALscreen message gives Avitar a much-enhanced marketing program. With the U.S. economy showing signs of recovering, our cost control program in effect and the capital environment improving, Peter's hiring is our next step in exploiting the growing opportunity for Avitar in the drugs-of-abuse market."
ABOUT AVITAR
Avitar, Inc. develops, manufactures and markets innovative and proprietary products in the oral fluid diagnostic market, disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Oral fluid diagnostics includes the estimated $1.5 billion drugs-of- abuse testing market, which encompasses the corporate workplace and criminal justice markets. Avitar's products include ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse. Additionally, Avitar manufactures and markets HYDRASORB(TM) an absorbent topical dressing for moderate to heavy exudating wounds. In the estimated $25 billion in vitro diagnostics market, Avitar is developing diagnostic strategies for disease and clinical testing. Some examples include influenza, diabetes and pregnancy. For more information, see Avitar's website at avitarinc.com.
Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
